Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma

Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma